"On January 2, 2022, Kintor Pharmaceutical announced that the first male subject has received a dosing in their phase 3 pivotal trial of pyrilutamide. The phase 3 trial of pyrilutamide in male androgenetic alopecia will include:
Randomized, double-blinded, placebo controlled parameters
- 416 male trial subjects
- A duration of 24 weeks/6 months
- A primary endpoint of change in number of non-vellus target area hair count from baseline to week 24
Kintor remains ambitious in this press release, which has become their M.O., and states that they intend to complete this trial by the end of 2022. Dr. Youzhi Tong, CEO of Kintor Pharma, had this to say: “We look forward to completing the planned 416 subjects enrollment by June 2022, and the follow-up medical evaluation(6 months study + 1 month follow-up)within the year. With the goal of completing the phase III clinical trial this year, we are speeding up the process and expecting that KX-826 would benefit global patients as soon as possible.“
Credit: Follicle Thought
Randomized, double-blinded, placebo controlled parameters
- 416 male trial subjects
- A duration of 24 weeks/6 months
- A primary endpoint of change in number of non-vellus target area hair count from baseline to week 24
Kintor remains ambitious in this press release, which has become their M.O., and states that they intend to complete this trial by the end of 2022. Dr. Youzhi Tong, CEO of Kintor Pharma, had this to say: “We look forward to completing the planned 416 subjects enrollment by June 2022, and the follow-up medical evaluation(6 months study + 1 month follow-up)within the year. With the goal of completing the phase III clinical trial this year, we are speeding up the process and expecting that KX-826 would benefit global patients as soon as possible.“
Credit: Follicle Thought
Kintor Begins KX-826 Phase 3 Trial For Androgenic Alopecia - Follicle Thought
Published on: Oct 7, 2020 at 20:04
www.folliclethought.com